Tretinoin - Roche

Drug Profile

Tretinoin - Roche

Alternative Names: Acnisdin Retinoico; All-trans retinoic acid; Arotinoid; Avita; Dermojuventus; Loderm Retinoico; NSC 122758; Retinoic acid; Retirides; Vesanoid; Vitamin A acid; Vitamin-A Acid; Vitanol

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bertek Pharmaceuticals; Ortho-McNeil; Roche
  • Developer Roche
  • Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne; Acne vulgaris; Acute promyelocytic leukaemia; Photodamage; Warts
  • Discontinued Emphysema

Most Recent Events

  • 20 Apr 2017 Tretinoin licensed to OncBioMune Pharmaceuticals in Mexico, Central America and Latin America
  • 10 Mar 2017 Vitel Laboratorios has been acquired by OncBioMune Pharmaceuticals
  • 03 Nov 2016 Vesanoid® sub-licensed to Vitel Laboratorios in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top